155 related articles for article (PubMed ID: 33090259)
21. Diagnostic performance of transperineal prostate targeted biopsy alone according to the PI-RADS score based on bi-parametric magnetic resonance imaging.
Noh TI; Shim JS; Kang SH; Cheon J; Kang SG
Front Oncol; 2023; 13():1142022. PubMed ID: 37035173
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI.
Campistol M; Morote J; Triquell M; Regis L; Celma A; de Torres I; Semidey ME; Mast R; Santamaría A; Planas J; Trilla E
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681685
[TBL] [Abstract][Full Text] [Related]
23. Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machine-Learning Techniques.
Montoya Perez I; Jambor I; Pahikkala T; Airola A; Merisaari H; Saunavaara J; Alinezhad S; Väänänen RM; Tallgrén T; Verho J; Kiviniemi A; Ettala O; Knaapila J; Syvänen KT; Kallajoki M; Vainio P; Aronen HJ; Pettersson K; Boström PJ; Taimen P
J Magn Reson Imaging; 2020 May; 51(5):1540-1553. PubMed ID: 31588660
[TBL] [Abstract][Full Text] [Related]
24. Prebiopsy biparametric MRI: differences of PI-RADS version 2 in patients with different PSA levels.
Choi MH; Lee YJ; Jung SE; Rha SE; Byun JY
Clin Radiol; 2018 Sep; 73(9):810-817. PubMed ID: 29895386
[TBL] [Abstract][Full Text] [Related]
25. Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study.
Falagario U; Jambor I; Taimen P; Syvänen KT; Kähkönen E; Merisaari H; Montoya Perez I; Knaapila J; Steiner A; Verho J; Tewari A; Aronen HJ; Carrieri G; Boström PJ; Ettala O
World J Urol; 2021 Jun; 39(6):1879-1887. PubMed ID: 32778912
[TBL] [Abstract][Full Text] [Related]
26. Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making.
Rajendran I; Lee KL; Thavaraja L; Barrett T
Br J Radiol; 2024 Jan; 97(1153):113-119. PubMed ID: 38263825
[TBL] [Abstract][Full Text] [Related]
27. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
28. Impact of biparametric prebiopsy prostate magnetic resonance imaging on the diagnostics of clinically significant prostate cancer in biopsy naïve men.
Knaapila J; Autio V; Jambor I; Ettala O; Verho J; Kiviniemi A; Taimen P; Perez IM; Aronen HJ; Syvänen KT; Boström PJ
Scand J Urol; 2020 Feb; 54(1):7-13. PubMed ID: 31914846
[No Abstract] [Full Text] [Related]
29. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
[TBL] [Abstract][Full Text] [Related]
30. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
31. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
[TBL] [Abstract][Full Text] [Related]
32. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
33. Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China.
Dai Z; Liu Y; Huangfu Z; Wang L; Liu Z
Med Sci Monit; 2021 Aug; 27():e930234. PubMed ID: 34365459
[TBL] [Abstract][Full Text] [Related]
34. The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging.
Kato D; Ozawa K; Takeuchi S; Kawase M; Kawase K; Nakai C; Takai M; Iinuma K; Nakane K; Kato H; Matsuo M; Suzui N; Miyazaki T; Koie T
Curr Oncol; 2021 Mar; 28(2):1294-1301. PubMed ID: 33809967
[TBL] [Abstract][Full Text] [Related]
35. Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data.
Remmers S; Kasivisvanathan V; Verbeek JFM; Moore CM; Roobol MJ;
Eur Urol Open Sci; 2022 Feb; 36():1-8. PubMed ID: 35098168
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of Bi-Parametric Magnetic Resonance Imaging with b=1,800 s/mm² Diffusion-Weighted Imaging for Diagnosing Clinically Significant Prostate Cancer.
Lee SS; Lee DH; Song WH; Nam JK; Han JY; Lee HJ; Kim TU; Park SW
World J Mens Health; 2020 Jul; 38(3):370-376. PubMed ID: 31385479
[TBL] [Abstract][Full Text] [Related]
37. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
39. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
40. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
